Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars

NCT ID: NCT07028567

Last Updated: 2025-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrophic scars present as depressions secondary to fibrous contractions. Subcision is a technique in which a needle is inserted under the acne scar to sever the fibrous tissue (tethers) that bind down the scar. This releases the fibrous tissue.

The original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) entails focal application of highly concentrated TCA (70% to 100%) with firm pressure applied to the entire atrophic area using a sharpened wooden applicator until frosting occurs.

Fillers containing hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid are increasingly used to correct atrophic acne scarring as they augment soft tissue in variable degree and are most effective in soft rolling or boxcar scars.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subcision Calcium Hydroxylapatite Trichloroacetic Acid Atrophic Acne Scar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Patients with atrophic acne scars.

Group Type EXPERIMENTAL

Calcium hydroxylapatite filler

Intervention Type DRUG

Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).

Painting chemical reconstruction of skin scars trichloroacetic acid technique

Intervention Type DRUG

Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcium hydroxylapatite filler

Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).

Intervention Type DRUG

Painting chemical reconstruction of skin scars trichloroacetic acid technique

Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 20 to 50 years.
* Both sexes.
* Patients with atrophic acne scars.

Exclusion Criteria

* Patients with Fitzpatrick skin phototypes V and VI.
* Receiving systemic isotretinoin medication at the time of the study.
* Active bacterial, viral or fungal infections in the treatment area.
* Hypertrophic scarring or keloidal tendency.
* Photosensitivity or photodermatitis.
* Unrealistic expectation, bleeding, coagulation disorders, and any other related skin disease.
* Pregnant or lactating females.
* Chronic debilitating diseases such as diabetes mellitus, cardiovascular diseases, renal failure, hepatic diseases, chronic respiratory diseases or any endocrine diseases.
* History of immunosuppressive drug intake or chemotherapy within 6 months before treatment.
Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Riham Mohamed ElSayed ElSetiha

Resident of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University

Tanta, El-Gharbia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36195/12/22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Subcision and Suction on Acne Scars
NCT01696513 ACTIVE_NOT_RECRUITING NA